Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing...
May 07, 2025 04:26 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb...
May 06, 2025 15:00 ET | Source: AgomAb Therapeutics N.V.

Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease

Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal...
May 06, 2025 04:04 ET | Source: Research and Markets

Ostomy Care Market Analysis and Forecast, 2025-2035, Featuring Strategic Profiles of Cymed Micro Skin, 3M Company, Braun, Alcare Co., Smith & Nephew and More

Dublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Ostomy Care Market - A Global and Regional Analysis: Focus on Surgery Type, Product, End User, and Region - Analysis and Forecast, 2025-2035" report has...
May 05, 2025 07:49 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April...
May 05, 2025 07:00 ET | Source: Alvotech

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Alvotech's and Teva's SELARSDI™ (ustekinumab-aekn) is now interchangeable with all presentations of the reference biologic Stelara®.
May 05, 2025 07:00 ET | Source: Alvotech

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April...
April 30, 2025 06:42 ET | Source: Research and Markets

Inflammatory Bowel Disease (IBD) Treatment Market 2025-2035: Biologics and Novel Drug Classes Propel IBD Treatment Market Forward

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market - A Global and Regional Analysis: Focus on Route of Administration, Drug Class, Distribution Channel,...
April 30, 2025 05:13 ET | Source: Research and Markets

Gastrointestinal (GI) Drugs Market 2025-2035 by Application, Route of Administration, Distribution Channel, Drug Class and Country - Advancements in Drug Development Fuel Growth of Gastrointestinal Treatments

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Gastrointestinal Drugs Market - A Global and Regional Analysis: Focus on Application, Route of Administration, Distribution Channel, Drug Class, and...
April 24, 2025 10:05 ET | Source: Research and Markets

Stoma/Ostomy Care Industry and Companies Analysis Report 2025-2030 Featuring 48 Market Players

Dublin, April 24, 2025 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Stoma/Ostomy Care was...